A bench headed by Justice G S Singhvi asked the Centre to file its response on a petition challenging the policy and raised questions on prices of medicines fixed by government.
"Margin of profit for manufacturers and dealers has become 10 per cent to 1300 per cent of the cost of manufacture of the drug," the bench said after going through a data provided by the petitioner in the PIL.
The bench also pulled up the Centre for dilly dallying on the issue of price fixation for the last 10 years and saying that nothing has been done by the Centre despite various committees including parliamentary committee deliberating on the issue.
While hearing another case, the court had earlier also slammed the government for not controlling the price of such drugs during the last 18 years.
The court had made it clear to the Centre that it should not form a pharma policy which may cause increase in the price of essential drugs.
The court had said drugs prescribed by the doctors were going beyond the reach of common man and "any formula for price fixation which goes against common man should be quashed".
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
